[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,80,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100568990","incentive-spirometry-to-improve-outcomes-in-lung-cancer-patients-undergoing-concurrent-chemotherapy-and-radiation-therapy-100568990",false,"NCT06688422","Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy","Incentive Spirometry for Respiratory Enhancement Pilot Clinical Trial in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy","INSPIRE-CRT","Inclusion Criteria:\n\n* Confirmed diagnosis of advanced non-small-cell lung cancer\n* Performance status (ECOG 0-1)\n* Eligible for concurrent chemotherapy and radiation\n* 18 years or older\n\nExclusion Criteria:\n\n* Previous lung or thoracic surgery\n* Enrollment in another pulmonary intervention trial\n* Home oxygen usage prior to enrolment\n* Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging\n* Presence of active respiratory tract infection\n* Uncontrolled nausea and vomiting\n* Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy\n* Inability or unwillingness of individual to give written informed consent","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are:\n\nDoes using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life?\n\nParticipants will:\n\nUse an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake.\n\nContinue using the spirometer daily during treatment and for up to three months after treatment.\n\nComplete quality of life assessments at the start of the study and at 3, 6, and 12 months.\n\nResearchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\\' well-being during and after their cancer treatment.",[27,28,29,30,31],"Lung Cancer","Pneumonitis","Radiation-Induced Lung Injury","Immunotherapy-Induced Pneumonitis","Non-Small-Cell Lung Cancer (NSCLC)",[33,34,35,36,37,38,39,40,41,42],"Incentive Spirometry","Chemotherapy","Radiation Therapy","Quality of Life (QoL)","Respiratory Complications","Advanced Lung Cancer","Concurrent Chemoradiotherapy","Pulmonary Toxicity","Immunotherapy Maintenance","Lung Function","RECRUITING","2026-04-13",{"date":46,"type":47},"2026-04-15","ACTUAL",{"date":49,"type":47},"2024-12-01",{"date":51,"type":21},"2026-12",{"name":53,"class":54},"The Cooper Health System","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":55},"100582225","phase-2-inhaled-budesonide-for-recurrence-prevention-and-adjuvant-therapy-in-checkpoint-inhibitor-pneumonitis-100582225","NCT06860542","Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis","Inclusion Criteria:\n\n1. Patients must be 18 years of age, or older on the day of signing informed consent and be willing and able to provide written informed consent\u002Fassent and, in the opinion of the Investigator, comply with protocol tests and procedures\n2. Patients require histologically confirmed solid tumour undergoing immune checkpoint inhibitor (ICI) therapy\n3. Diagnosis of first documented diagnosis of Checkpoint Inhibitor Pneumonitis (CIP) made per European Society for Medical Oncology (ESMO)\u002FAmerican Society for Medical Oncology (ASCO) guidelines with severity \\>\u002Fgrade 2 by Common Terminology Criteria for Adverse Events (CTCAE)v5.0\n\n   a. Per ASCO\u002FESMO consensus guidelines, workup must include a compatible clinical picture, plus\u002Fminus supporting radiographic evidence (chest x-ray or preferably computed tomography (CT)), combined with clinical and\u002For microbiologic ruling out of alternative etiologies including infections or pulmonary disease progression. This includes a negative COVID test. Bronchoscopic sampling is not required, but can be considered.\n4. Be able to effectively operate and use budesonide delivery method (Turbuhaler®), either independently or with aid of caregiver who anticipates being able to do so throughout trial period\n5. Have adequate organ function, as judged by enrolling clinician\n6. Females of childbearing potential have a negative urine or serum pregnancy test prior to study day 1. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses for at least 1 year\n7. Females of childbearing potential are willing to use contraception or abstain from heterosexual sexual contact for the course of the study\n\nExclusion Criteria:\n\n1. Diagnosis of interstitial lung disease (ILD) active (clinically and radiologically evident) within last year prior to diagnosis of CIP\n2. Clinically suspected significant lung disease for which inhaled steroid would be standard of care (moderate asthma or severe chronic obstructive pulmonary disease (COPD)) and for which randomization to no inhaled steroids (control arm) would not represent optimal medical care. Based on enrolling physicians judgement; spirometry\u002Fpulmonary function tests are NOT required to assess this exclusion criteria.\n3. Current (within last two weeks), active (not medically able or unwilling to discontinue prior to treatment start) and regular (2 or more times per week) use of inhaled steroids (for any indication) or systemic (\\>10mg prednisone equivalent) corticosteroids (for indication other than CIP) at time of randomization\n4. Receiving systemic, non-chemotherapy immunosuppressive agent at time of randomization (hydroxychloroquine is acceptable)\n5. Use of a medication with significant interaction with inhaled budesonide (HIV protease inhibitors, ketoconazole or other potent CYP3A4 inhibitors), unless deemed required and safe by co-investigator.\n6. Known poorly controlled diabetes, defined as A1c \\>10, prior to initiation of steroids for CIP\n7. History of active and unstable systemic disease, including heart failure New York Heart Association (NYHA) III or IV, cirrhosis with Child Pugh B or C, Renal Failure with creatinine clearance (CrCl) \\\u003C30 per Cockcroft-Gault formula, or other unstable life limiting condition as determined by trial investigators\n8. Current or prior participation in a study of an investigational agent or device within 4 weeks of randomization\n9. History or current evidence of any condition, therapy, or laboratory abnormalities which might confound trial results, interfere with the patient's participation for the full duration of the trial, or otherwise causing it to be not in the best interest of the patient to participate in the trial, in the opinion of the treating investigator.\n10. Is or has an immediate family member (e.g., spouse, parent\u002Flegal guardian, sibling or child) who is directly involved with this trial, unless prospective ethics board approval (by chair or designee) is given allowing exception to this criterion for a specific patient\n11. Breastfeeding is not permitted during the duration of trial participation.",{"count":63,"type":21},94,[65],"PHASE2","The introduction of immune checkpoint inhibitors (immunotherapy) that stimulate our immune system to recognize and attack cancer cells has been one of the most exciting advances in oncology over the last decade. These medications are now employed across almost half of cancer types and settings, however they come with a cost. In some patients, instead of attacking cancer cells alone, the stimulated immune system damages healthy tissues (immune related adverse events), with one of the most severe and potentially deadly such complications being immune attack on the lungs, or checkpoint inhibitor pneumonitis (CIP). When treated promptly with oral or intravenous steroids, acute CIP improves in many cases, however for approximately one-fifth of patients the lung inflammation is difficult to control, resulting in recurrent shortness of breath, the need for extended courses of oral or intravenous steroids, impacting quality of life and cancer therapy decisions. The goal of the trial is to assess whether use of inhaled steroids, a type of medication commonly used in asthma patients, for one year after a first diagnosis of CIP may help the lung inflammation resolve and not return, without the repeated use of oral or intravenous medications that carry more side effects.",[28,68],"Immune-related Adverse Event",[68,70],"Checkpoint Inhibitor Pneumonitis","2026-03-19",{"date":73,"type":47},"2026-03-23",{"date":75,"type":47},"2026-02-10",{"date":77,"type":21},"2030-12-01",{"name":79,"class":54},"AHS Cancer Control Alberta",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":55},"100474218","phase-1-single-cell-sequencing-of-blf-to-guide-the-treatment-of-radiation-pneumonitis-or-immune-checkpoint-inhibitor-pneumonitis-100474218","NCT05455034","Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis","Single-cell Sequencing of Bronchoalveolar Lavage Fluid to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis","Inclusion Criteria:\n\n1. Informed consent has been signed, and according to the judgment of the investigator, the patient can comply with the study protocol and sign the written informed consent;\n2. NSCLC patients who have been clinically diagnosed with RP or CIP after histopathologically confirmed radiotherapy or immunocheckpoint inhibitor treatment and have not received glucocorticoid or other drugs.\n3. ≥18 years old, less than 75 years old;\n4. ECOG PS score 0-3 in the Eastern Tumor Collaboration group;\n5. Patients without contraindications to alveolar lavage;\n\nExclusion Criteria:\n\n1. Poor patient compliance and violation of test regulations;\n2. Liver and kidney dysfunction, such as myocardial infarction, angina pectoris, liver transaminase significantly increased;\n3. Had any medical condition requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to enrollment;\n4. Severe infection occurred within 4 weeks prior to enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia;\n5. Severe chronic or active infections (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic treatment within 14 days prior to enrollment;\n6. Untreated patients with chronic hepatitis B, HBV carriers with HBV DNA≥ 500 IU\u002FmL, or patients with active hepatitis C virus (HCV) should be excluded. Note: Non-active hepatitis B, surface antigen (HBsAg) carriers, treated and stable hepatitis B carriers (HBV DNA \\& LT; 500 IU\u002FmL), patients with cured hepatitis C could be enrolled;\n7. Known history of HIV infection;\n8. Received any other investigational drug or participated in any other clinical trial within 28 days.","80 Years",{"count":89,"type":21},40,[91,65],"PHASE1","A multicenter, exploratory clinical research, to map the radiation or immune checkpoint inhibitor pneumonitis in patients with alveolar lavage single-celled map. Find out the pathogenesis and prevention strategies of radiation or immune checkpoint inhibitor pneumonitis. Specific treatment is given based on the recommendation of the treatment guidelines for radiation or immune checkpoint inhibitor pneumonitis and the results of single cell sequencing, which will become a new technology for clinical application.",[28],[95,96,97,98],"Single-cell Sequencing","Radiation Pneumonitis","Immune Checkpoint Inhibitor Pneumonitis","Bronchoalveolar Lavage Fluid","2025-07-11",{"date":101,"type":47},"2025-07-14",{"date":103,"type":47},"2023-08-01",{"date":105,"type":21},"2025-12-30",{"name":107,"class":54},"Xinqiao Hospital of Chongqing",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100567644","a-study-on-the-combination-therapy-of-eravacycline-for-treating-carbapenem-resistant-acinetobacter-baumannii-pneumonia-100567644","NCT06670872","A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Voluntarily participating in this study and signing an informed consent form. If the subject is unable to read and\u002For sign the informed consent form due to lack of capacity or other reasons, the informed process and the informed consent form must be signed by their legal guardian.\n3. Patients with clinical manifestations and imaging results consistent with bacterial pneumonia, and who are expected to benefit from antimicrobial treatment. Suspected carbapenem-resistant Acinetobacter baumannii infection or Acinetobacter baumannii detected in two consecutive sputum cultures (at least one of which must be from bronchoalveolar lavage or endotracheal aspirate), with resistance to carbapenems.\n4. Patients who have been treated with eravacycline for at least 3 days.\n\nExclusion Criteria:\n\n1. The investigator believes that there are any medical history, current condition, treatment, abnormal laboratory test results, or other situations that may affect the trial results, interrupt the trial process (or the subject cannot complete all trial requirements, operations, and visits), or increase the risk to the subject from receiving the trial medication, including patients with terminal illness, or evidence of an immediately life-threatening disease.\n2. Patients with a history of allergic reactions to tetracyclines or any excipients contained in the formulation of the study medication.",{"count":115,"type":21},50,"28 Days","OBSERVATIONAL","This study intends to evaluate the efficacy and safety of eravacycline-based combination therapy in real words for Chinese patients with CRAB pneumonia, providing data reference for clinical treatment of CRAB pneumonia.",[28,120],"Acinetobacter Baumannii",[122],"Eravacycline","NOT_YET_RECRUITING","2024-10-31",{"date":126,"type":47},"2024-11-01",{"date":128,"type":21},"2024-10",{"date":130,"type":21},"2026-10",{"name":132,"class":54},"Peking University Third Hospital",2]